Axsome Therapeutics, Inc. (AXSM)
Axsome Therapeutics Dives Again On Its Second Big Drug Failure In A Week
Axsome Therapeutics posted mixed results for its experimental depression treatment on Tuesday, leading Axsome stock to dive. The post Axsome Therapeutics Dives Again On Its Second Big Drug Failure In A Week appeared first on Investor's Business Daily.
Axsome's depression treatment fails to meet main goal of late-stage study
Axsome Therapeutics said on Tuesday its experimental drug to treat major depressive disorder failed to meet the main goal of a late-stage study.
AXSM Stock Down Despite ADHD Study Meeting Primary Endpoint
Axsome's phase III FOCUS study, evaluating solriamfetol for treating attention deficit hyperactivity disorder, meets its primary and key secondary endpoints.
Axsome Therapeutics' ADHD drug meets main goal in late-stage study
Axsome Therapeutics said on Tuesday its experimental drug to treat attention deficit hyperactivity disorder (ADHD) met the main goal in a late-stage study.
Will Auvelity & Other Drugs Aid AXSM's Growth Amid Stiff Competition?
Axsome's depression drug, Auvelity, is driving the top line while Sunosi diversifies its business. The recent FDA nod for Symbravo also bodes well.
AXSM Settles Sunosi Patent Litigation With Hikma Pharmaceuticals
Axsome enters into a settlement agreement with Hikma Pharmaceuticals to resolve a patent litigation related to Sunosi.
AXSM Gets Positive FDA Feedback for Alzheimer's Agitation Drug Filing
Based on the FDA's feedback, Axsome plans to submit a supplemental NDA for AXS-05 in Alzheimer's disease agitation in third-quarter 2025.
Axsome Says Symbravo Hits Primary Goal In Late-Stage Migraine Trial In Patients Experiencing Inadequate Response To Commonly Used Drugs
On Monday, Axsome Therapeutics, Inc. AXSM announced that the EMERGE Phase 3 trial of Symbravo (MoSEIC meloxicam and rizatriptan) in patients experiencing inadequate response to oral CGRP inhibitors (most commonly used drugs for migraine) met its primary endpoint.
Axsome Q4 Earnings: Revenues Rising, Skepticism Lingering
Axsome Q4 Earnings: Revenues Rising, Skepticism Lingering
Axsome Q4 Loss Wider Than Expected, Auvelity Drives Sales Growth
AXSM's fourth-quarter 2024 earnings miss estimates while revenues beat the same. Net product sales rise year over year.
Axsome Therapeutics, Inc. (AXSM) Q4 2024 Earnings Call Transcript
Axsome Therapeutics, Inc. (NASDAQ:AXSM ) Q4 2024 Earnings Conference Call February 18, 2025 8:00 AM ET Company Participants Darren Opland - Director, Corporate Communications Herriot Tabuteau - Chief Executive Officer Nick Pizzie - Chief Financial Officer Ari Maizel - Chief Commercial Officer Mark Jacobson - Chief Operating Officer Hunter Murdock - General Counsel Conference Call Participants Ram Selvaraju - H.C. Wainwright Charles Duncan - Cantor Fitzgerald Asim Rana - Truist Securities Joseph Thome - TD Cowen David Hoang - Deutsche Bank David Amsellem - Piper Sandler Marc Goodman - Leerink Partners Graig Suvannavejh - Mizuho Securities Vikram Purohit - Morgan Stanley Leonid Timashev - RBC Capital Markets Cerena Chen - Wells Fargo Ami Fadia - Needham & Company Yatin Suneja - Guggenheim Partners Myles Minter - William Blair Operator Good morning, and welcome to the Axsome Therapeutics Fourth Quarter and Full Year 2024 Conference Call.
Axsome Therapeutics (AXSM) Reports Q4 Loss, Tops Revenue Estimates
Axsome Therapeutics (AXSM) came out with a quarterly loss of $0.96 per share versus the Zacks Consensus Estimate of a loss of $1. This compares to loss of $0.73 per share a year ago.
